ClinicalTrials.gg
CompletedNCT07646548Updated Oct 29, 2026

Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy Participants

A Phase 1 interventional study of Dupilumab coformulated with berahyaluronidase alfa and Dupilumab in Healthy Volunteers, sponsored by Sanofi. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Sanofi · Phase 1, Interventional, and Basic science

Updated Oct 29, 2026Now CompletedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This is a Phase 1 study with 2 parallel groups of healthy participants. Participants will be randomized to receive either a subcutaneous (SC) dose of dupilumab coformulated with berahyaluronidase alfa or a SC dose of dupilumab without berahyaluronidase alfa.

The purpose of this study is to assess the pharmacokinetic (PK) characteristics of a single SC dose of dupilumab coformulated with berahyaluronidase alfa and dupilumab without berahyaluronidase alfa in healthy participants aged ≥18 and ≤60 years.

Study details include:

  • The study duration will be approximately up to 12 to 15 weeks.
  • The treatment will be administered as a single dose on Day 1.
  • The number of visits will be 14.
02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and/or female participant, between 18 and 60 years of age, inclusive, at the time of signing the .
  • Determined to be healthy by the Investigator using a comprehensive clinical assessment (detailed medical history and complete physical examination).
  • Body weight between 50.0 and 100.0 kg, inclusive.
  • between 18.0 and 32.0 kg/m2 (inclusive).

Exclusion criteria

Exclusion Criteria:

  • Any history or presence of cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, dermatological, osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease, or signs of acute illness.
  • Frequent headaches and/or migraine, recurrent nausea and/or vomiting (for vomiting only: more than twice a month).
  • Blood donation, any volume, within 2 months before inclusion.
  • Symptomatic postural hypotension, irrespective of the decrease in blood pressure, or asymptomatic postural hypotension defined as a decrease in SBP of ≥30 mmHg within 3 minutes when changing from supine to standing position.
  • Presence or history of drug , or clinically significant allergic disease as diagnosed and treated by a physician. Participants with known hypersensitivity to any of the study interventions, or components thereof.
  • History or presence of drug or alcohol abuse (alcohol consumption more than 40 g per day on a regular basis).
  • Regular smoking of more than 5 cigarettes or equivalent in nicotine per week, unable to stop smoking during the study (occasional smoker can be enrolled).
  • Excessive consumption of beverages containing xanthine bases (more than 4 cups or glasses per day).
  • If female, pregnancy (defined as positive urine pregnancy test); breast-feeding.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Treatment A

    Participants will receive a subcutaneous (SC) dose of dupilumab coformulated with berahyaluronidase alfa on Day 1

    Biological: Dupilumab coformulated with berahyaluronidase alfa

  • Experimental
    Treatment B

    Participants will receive a SC dose of dupilumab without berahyaluronidase alfa on Day 1

    Biological: Dupilumab

Interventions

  • BiologicalDupilumab coformulated with berahyaluronidase alfa

    Drug page: Dupilumab

    Pharmaceutical form: Solution for injection Route of administration: Subcutaneous injection

    Also known as: SAR231893, Dupixent

  • BiologicalDupilumab

    Pharmaceutical form: Solution for injection Route of administration: Subcutaneous injection

    Also known as: SAR231893, Dupixent

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic (PK) parameter in serum: Cmax of dupilumab

    Cmax: Maximum concentration observed in serum

    Time frame: From Day 1 to Day 85 (end of study)

  2. PK parameter in serum: AUClast of dupilumab

    AUClast: Area under the concentration in serum versus time curve calculated using the trapezoidal method from time zero to the real time tlast

    Time frame: From Day 1 to Day 85 (end of study)

Secondary outcomes

  1. Number of participants with treatment-emergent adverse events (TEAEs), serious TEAEs, injection site reactions and clinically significant laboratory values and vital signs

    Time frame: From Day -1 to Day 85.

  2. Number of participants with antidrug antibody to dupilumab and berahyaluronidase alfa

    Time frame: On Day 1, Day 43 and Day 85

07

Study locations

1 site
  • Clinical Pharmacology of Miami- Site Number : 8400001
    Hialeah, Florida 33014, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2026 to primary completion in Sep 2026, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2026
First posted
Jun 12, 2026
StartActual
Jun 11, 2026
Primary completionActual
Sep 30, 2026
CompletionActual
Sep 30, 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Active, not recruiting→Completed
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07646548
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jun 12, 2026
Start date
Jun 11, 2026
Primary completion
Sep 30, 2026
Completion
Sep 30, 2026
Last update
Oct 29, 2026

Study contacts

Angel Lamas, MD
principal investigator · Clinical Pharmacology of Miami (CPMI)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion